We've tried to summarize the data from some of the stock subreddits here into different categories. The categories are Recent Posts, Due Diligence (DD), Discussions or News. The News here is usually not the news in media but still very relevant information.
| Date | Title | Subreddit | Price |
|---|
| Date | Title | Subreddit | Price |
|---|---|---|---|
| Jun-03-2021 | Nat Gas is gonna Rip Some Ass [CLNE | wallstreetbets | 2.21 |
| Jan-06-2022 | Tiziana Life Sciences to Participate in 2022 Biotech Showcase Virtual Investor Conference | 1.005 | 0.00 |
| Oct-20-2021 | Tiziana Life Sciences plc: PDMR Dealing | 1.47 | 0.00 |
| Oct-20-2021 | Tiziana Life Sciences - Scheme Effective Date | 1.47 | 0.00 |
| Sep-28-2021 | Tiziana Life Sciences plc: PDMR Dealing | 1.57 | 0.00 |
| Sep-27-2021 | Tiziana Life Sciences half-term report reveals it has made progress on all fronts | 1.51 | 0.00 |
| Sep-27-2021 | Tiziana Life Sciences' half-term report reveals it has made progress on all fronts | 1.51 | 0.00 |
| Sep-27-2021 | Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting | 1.57 | 0.00 |
| Date | Title | Subreddit | Price |
|---|---|---|---|
| May-26-2021 | Tiziana Announces Initiation of Clinical Trial in the Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program | wallstreetbets | 2.48 |
| May-14-2021 | I don't understand $TSLA | stocks | 2.31 |
| Date | Title | Subreddit | Price |
|---|---|---|---|
| Jan-10-2022 | TLSA continues to invest in America! | wallstreetbets | 0.94 |
| May-26-2021 | Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers. | StockMarket | 2.40 |
| May-26-2021 | Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers. | StockMarket | 2.49 |
| May-25-2021 | Tiziana Announces Initiation of Clinical Trial in the Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program | StockMarket | 2.39 |
| Apr-13-2021 | Breast Cancer Advancement x Accustem Sciences Limited in the U.S. | StockMarket | 2.78 |